跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

BAYER AUSTRALIA LTD

首页临床试验发起方与机构BAYER AUSTRALIA LTD

BAYER AUSTRALIA LTD

500 Wellington Road, Mulgrave, Victoria, 澳大利亚

别名:

bayer crop

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

6

0 进行中

药物批准

474

批准总数

监管机构

2

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

3 期

4

66.7%

2 期

2

33.3%

试验状态分布

已完成

6

100.0%

相关临床试验

该机构主办的试验（6）

A clinical study to determine the safety and efficacy of gadobutrol 1.0 molar (Gadovist 'Registered trade mark') in comparison to ProHance 'Registered trade mark' (gadoteridol) 0.5 molar in patients referred for contrast-enhanced Magnetic Resonance Imaging (MRI) of the central nervous system.

Sep 2008402 名受试者

A phase III randomised, placebo-controlled study of Sorafenib in repeated cycles of 21 days in combination with paclitaxel / carboplatin chemotherapy in patients with unresectable stage III or IV melanoma.

Oct 2005250 名受试者

A Phase III randomised study of BAY 43-9006 in patients with unresectable and/or metastatic renal cell cancer

Oct 2005884 名受试者

A Phase III randomized, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinoma

Oct 2005602 名受试者

Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The Einstein-DVT dose-finding study.

Oct 2005520 名受试者

Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein Thrombosis. A phase II dose finding and proof of principle trial.ODIXa-DVT

Oct 2005600 名受试者

药物批准

按机构分类的批准

NMPA

National Medical Products Administration

6

药物批准

TGA

Therapeutic Goods Administration

468

药物批准

近期批准

Rennie Spearmint Flavour (517726)

Rennie Spearmint Flavour (517726)

Berocca Hydrate effervescent tablets grapefruit flavour (512654)

Berocca Hydrate effervescent tablets grapefruit flavour (512654)

Berocca Energy Effervescent Tablet Strawberry Flavour (508474)

Berocca Energy Effervescent Tablet Strawberry Flavour (508474)

Berocca Energy Effervescent Tablets Variety Pack (4x15 effervescent tablets new formulation) (496982)

Berocca Energy Effervescent Tablets Variety Pack (4x15 effervescent tablets new formulation) (496982)

Berocca Energy Effervescent Tablets Raspberry Blackcurrant Flavour (493008)

Berocca Energy Effervescent Tablets Raspberry Blackcurrant Flavour (493008)

资讯

暂无资讯文章

本页目录

概览
相关临床试验6
药物批准474
资讯

返回机构列表